Melbourne, Nov 19, 2007 AEST (ABN Newswire) - The Directors of Solagran Limited are pleased to release a letter received from Dr Nina Golovkina, the Head of the Department of Psychosomatics at the Skvortsova- Stepanova Psychiatric Hospital in St Petersburg, confirming the very positive results of trials conducted by that hospital, involving the use of:
- Ropren and Bioeffective A to treat conditions associated with alcoholism and drug addiction, and
- Ropren to treat neurodegenerative disorders like Alzheimer's disease and Parkinson's disease.
The attached letter makes a number of clear statements about the impact of treatment with Ropren on Alzheimer's patients, and treatment with both Ropren and Bioeffective A on heroin-addicted, chronic alcoholics.
In relation to Ropren, Dr Golovkina states that this substance "had a special positive effect on the Central Nervous System (CNS), leading to regression of focal microsymptoms and improvement in memory and alertness (particularly in cases of Alzheimer's and Parkinson's diseases). This enables restoration of lost CNS functions and enhances the ability of patients to look after themselves".
In relation to Bioeffective A, she states that: "This therapeutic substance has a very positive effect on the peripheral nervous system, by reducing and then removing symptoms of polyneuropathy .... There were also some improvements in EEG parameters, expressed through normalisation of alpha-rhythm and absence of any fits during the treatment period."
Solagran is not yet in a position to release the full results of these trials, due to ongoing patent protection work. They will be released as soon as practicable. But Dr Golovkina's letter provides a clear indication of the nature of the results. In the opinion of the Directors, the commercial implications of these trials results are significant.
Dr Golovkina was present at the Solagran EGM in September and made a short presentation summarising the outcomes of trials referred to in her letter. At the meeting, she was asked by a shareholder if her hospital would use Ropren to treat these conditions once it was available. She indicated that a decision to that effect had already been taken by the hospital administration and that this decision was communicated to Solagran in a preliminary report from the hospital's Director, Dr Vladimir Agishev, in late 2006. [Key elements of this report were released to the market in an announcement dated 19 October 2006].
The Directors believe that this off-label use of Ropren in Russia will have a positive effect on revenues. It will accelerate take-up in the short term. However the fact that Ropren will be supply constrained initially means that the real impact of these incremental revenues will not be felt until 2009-10.
Attachment
1. Letter from Dr Golovkina dated 9 November, 2007 (in Russian and English)
HEALTHCARE COMMITTEE
Sankt-Petersburg State Medical Authority
I.I. SCVORTSOVA-STEPANOVA MUNICIPAL PSYCHIATRIC HOSPITAL NO. 3
197341, St Petersburg, Fermskoe Shosse, No. 36
Tel.: (812) 301-0437 Fax: (812) 301-8654
E-mail: bps3@zdrav.spb.ru
9 November 2007
Evaluation of practical effect of therapeutic substances Ropren (drops) and Bioeffective A (capsules)
Results of the trials conducted confirm that both therapeutic substances are effective for the treatment of patients with alcohol addiction at both the 2nd and 3rd degree of expression of the pathology.
In general, this pathology leads to problems in psychological conditions including increased likelihood of convulsion, disruption of consciousness (hallucinations), increased disposition towards suicide and in some cases to death.
These therapeutic substances quickly and effectively arrested signs of alcohol-abstinence syndrome. This was evident through improved functioning of the cardiovascular system, pancreas, liver, and organs of haemopoiesis. Their use also led to rapid improvement in the physical condition of patients together with a reduction in suffering, as evidenced by:
- Normalisation of sleep patterns and blood pressure;
- Disappearance of hallucinations;
- Improvement in memory and alertness;
- Improvement in neurological status including alcoholic polyneuropathy (restoration of balance, reduction in pain in gastrocnemius muscles, and the ability to walk independently);
- A re-awakened interest in life;
- Improvement in the quality of life.
Comparative evaluation of these therapeutic substances
1. Ropren (drops) When compared to Bioeffective A, Ropren is a more active substance and its therapeutic effect is evident earlier.
- Improvement in biochemical blood indices occurs a good deal earlier, with restoration of levels of bilirubin and transaminase. This indicates faster restoration of liver function and acceleration of the body's detoxification processes.
- Ropren has a special positive effect on the Central Nervous System (CNS), leading to regression of focal micro-symptoms and improvement in memory and alertness (particularly in cases of Alzheimer's and Parkinson's diseases). This enables restoration of lost CNS functions and enhances the ability of patients to look after themselves.
- Ropren treatment also led to an accelerated the rate of recovery after such diseases as pneumonia, steatosis and cirrhosis of the liver, as well as a reduction in the symptoms of ascites.
2. Bioeffective A (capsules)
This therapeutic substance has a very positive effect on the peripheral nervous system, by reducing and then removing symptoms of polyneuropathy.
Normally, the process of restoration of these functions takes about 2-3 months, however, after Bioeffective A therapy the first signs of improvement were evident as early as the end of the first week. In some cases, patients were discharged from the hospital and went home independently after 1 month of this therapy.
There were also some improvements in EEG parameters, expressed through normalisation of α- rhythm and absence of any fits during the treatment period.
Conclusion
Treatment with the therapeutic substances studied (Ropren and Bioeffective A) led to a significant shortening of the recovery period of the body, with virtual absence of any side effects.
These medications are particularly interesting due to their plant origin, ecologically clean nature, and the elimination of any need for additional therapeutic substances, such as nootropics, antioxidants or vitamins, since the substances studied exhibit the properties of all these groups. They act rapidly and effectively, and their use prevents occurrence of side effects.
There is no doubt that the studied medications will find widespread application in the treatment of exogenic alcohol and toxic poisonings, for both drug users and alcoholics.
They will also be useful in restoring lost functions in the case of Alzheimer's disease.
Golovkina N.P.
Head of Department of Psychosomatics
Contact
Denis Kilroy
Executive Director
Solagran Limited
TEL: +61 3 9820 2699
MOB: +61 411 222 844 (m)
www.solagran.com
| ||
|
